The Committee adopted a positive opinion by consensus supporting the introduction of a new oral suspension pharmaceutical form at a strength of 2 mg/ml, together with the CHMP Assessment Report and translation timetable. (European Medicines Agency) - Aug 30, 2026 - CHMP Final
Minutes of the meeting on 23 - 26 Feb 2026: CHMP confirmed that all previously identified issues in the extension application had been addressed."
CHMP • Immunology
|